The table
This is the short version of the comparison hub on this site, which explains each row at length. Every entry comes from the FDA-approved prescribing information for the branded products, the two reference trials on PubMed, or Bodi Envi’s Plans page. The two labels report different trials with different designs and cannot be compared directly with each other; both say so, and the rows are set side by side for reading, not for ranking.
| Row | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism, per the labels | GLP-1 receptor agonist; a GLP-1 analogue with 94 percent homology to human GLP-1 | GIP receptor and GLP-1 receptor agonist; activates both |
| FDA-approved products | Wegovy® (weight management and other indications); Ozempic® (type 2 diabetes) | Zepbound® (weight management; obstructive sleep apnea in adults with obesity); Mounjaro® (type 2 diabetes) |
| Half-life, per the labels | Approximately one week | Approximately five days |
| Label starting dose | 0.25 mg once weekly for four weeks | 2.5 mg once weekly for four weeks, not a maintenance dose |
| Label escalation | Steps every four weeks through 0.5, 1 and 1.7 mg | Steps of 2.5 mg after at least four weeks on a dose |
| Label maintenance doses for weight reduction | 1.7 mg or 2.4 mg, with 7.2 mg described for some adults | 5 mg, 10 mg or 15 mg; 15 mg maximum |
| Reference trial | STEP 1, 1,961 adults, 68 weeks | SURMOUNT-1, 2,539 adults, 72 weeks |
| Mean weight change in the trial | 14.9 percent at 2.4 mg against 2.4 percent placebo | 15.0, 19.5 and 20.9 percent at 5, 10 and 15 mg against 3.1 percent placebo |
| Share losing at least 5 percent | 86.4 percent against 31.5 percent | 85, 89 and 91 percent against 35 percent |
| Most common side effect, per the labels | Nausea, 44 percent against 16 percent placebo | Nausea, 25 to 29 percent against 8 percent placebo |
| Discontinued for adverse reactions, per the labels | 6.8 percent against 3.2 percent | 4.8, 6.3 and 6.7 percent against 3.4 percent |
| Boxed warning | Thyroid C-cell tumours in rodents | Thyroid C-cell tumours in rats |
| Bodi Envi compounded program, monthly | $155 per month | $229 per month |
| Bodi Envi compounded program, 12 month plan | $125 per month, $1,500 paid once | $175 per month, $2,100 paid once |
Reading the rows
The mechanism row is the real difference. The Wegovy® label describes semaglutide as selectively binding to and activating the GLP-1 receptor; the Zepbound® label describes tirzepatide as selectively binding to and activating both the GIP and GLP-1 receptors, and says nonclinical studies suggest the addition of GIP may further contribute to the regulation of food intake. The guides on this site to each molecule explain what that means.
The dose rows describe the branded products and are not advice. With a compounded prescription, which is what Bodi Envi’s programs may include, a licensed provider sets the dose and any change to it, and the pharmacy label gives the measuring instructions for the vial.
The trial rows are means across thousands of participants on the branded products, alongside diet and physical activity, over more than a year. They are not predictions for anyone, the spread around them was wide, and no trial of that size has studied personalized compounded semaglutide or tirzepatide. The side effect rows come from each label’s adverse reaction table and from different trials.
The price rows are Bodi Envi’s published program prices, the same at every dose, including the provider review, care team messaging, a GLP-1 ebook and diet plan, and the medication when prescribed. Completing an assessment does not guarantee a prescription.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
How each is taken
Both are injected under the skin once a week, in the abdomen, thigh or upper arm, with the injection site rotated, and both labels say the medication is to be used with a reduced calorie diet and increased physical activity. The labels differ on missed doses: the Wegovy® label says a missed dose is taken if the next is more than two days away and otherwise skipped, with escalation restarted at a lower dose after two or more consecutive missed doses, while the Zepbound® label says a missed dose may be taken within four days and is otherwise skipped. The Zepbound® label alone advises people using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for four weeks after starting and after each dose increase. Both labels carry the same set of warnings, from pancreatitis and gallbladder disease to kidney injury from dehydration and low blood sugar with insulin or a sulfonylurea.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What the table cannot tell you
Which medication is appropriate for you. That is a clinical decision for a licensed provider, through Wasef Health, PC for applicable Bodi Envi programs, made from your health history, your current medications, your goals and the labels’ contraindications and warnings, which the safety guide on this site sets out. The comparison hub explains how a provider chooses between the two.
Personalized Compounded semaglutide and tirzepatide are not FDA-approved and are not equivalent to Wegovy®, Ozempic®, Zepbound® or Mounjaro®; the FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed. Brand names are trademarks of their respective owners and Bodi Envi is not affiliated with them. This is general information and not medical advice, and your provider is the person to ask.